An Open-Label, Single-Arm Phase II Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-Naive Multiple Myeloma Patients Non-Eligible for Autologous Stem-Cell Transplantation
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IDEALL
- Sponsors Takeda
- 13 Aug 2019 Planned initiation date changed from 31 Jul 2019 to 30 Sep 2019.
- 14 Jun 2019 Planned initiation date changed from 30 May 2019 to 31 Jul 2019.
- 06 Aug 2018 New trial record